Telo Genomics Corp. (TDSGF)
USD 0.06
(-0.34%)
USD 0.06
(-0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.88 Million CAD | -33.66% |
| 2022 | -2.11 Million CAD | -96.56% |
| 2021 | -1.07 Million CAD | 11.64% |
| 2020 | -1.21 Million CAD | -15.34% |
| 2019 | -1.05 Million CAD | 76.61% |
| 2018 | -4.5 Million CAD | 51.57% |
| 2017 | -9.3 Million CAD | -12555.13% |
| 2016 | -73.49 Thousand CAD | 34.29% |
| 2015 | -111.84 Thousand CAD | -144.67% |
| 2014 | -45.71 Thousand CAD | 62.82% |
| 2013 | -122.96 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -615.04 Thousand CAD | 26.13% |
| 2024 Q1 | -672.54 Thousand CAD | 21.33% |
| 2024 Q2 | -833.97 Thousand CAD | -24.0% |
| 2023 Q1 | -615.8 Thousand CAD | 5.73% |
| 2023 FY | -2.82 Million CAD | -33.66% |
| 2023 Q2 | -639.21 Thousand CAD | -3.8% |
| 2023 Q3 | -710.88 Thousand CAD | -11.21% |
| 2023 Q4 | -854.87 Thousand CAD | -20.25% |
| 2022 Q2 | -463.29 Thousand CAD | 3.27% |
| 2022 Q1 | -478.94 Thousand CAD | -66.2% |
| 2022 FY | -2.11 Million CAD | -96.56% |
| 2022 Q4 | -653.23 Thousand CAD | -26.85% |
| 2022 Q3 | -514.98 Thousand CAD | -11.16% |
| 2021 FY | -1.07 Million CAD | 11.64% |
| 2021 Q3 | -309.6 Thousand CAD | -13.07% |
| 2021 Q2 | -273.81 Thousand CAD | -38.24% |
| 2021 Q1 | -198.07 Thousand CAD | 35.52% |
| 2021 Q4 | -288.17 Thousand CAD | 6.92% |
| 2020 FY | -1.21 Million CAD | -15.34% |
| 2020 Q1 | -138.64 Thousand CAD | 24.57% |
| 2020 Q2 | -561.04 Thousand CAD | -304.67% |
| 2020 Q3 | -321.42 Thousand CAD | 42.71% |
| 2020 Q4 | -307.16 Thousand CAD | 4.44% |
| 2019 Q2 | -176.02 Thousand CAD | 69.61% |
| 2019 FY | -1.05 Million CAD | 76.61% |
| 2019 Q4 | -183.79 Thousand CAD | -60.59% |
| 2019 Q3 | -114.44 Thousand CAD | 34.98% |
| 2019 Q1 | -579.25 Thousand CAD | 42.06% |
| 2018 Q2 | -1.55 Million CAD | -45.41% |
| 2018 FY | -4.5 Million CAD | 51.57% |
| 2018 Q4 | -999.79 Thousand CAD | -13.22% |
| 2018 Q3 | -883.08 Thousand CAD | 43.15% |
| 2018 Q1 | -1.06 Million CAD | 50.69% |
| 2017 FY | -9.3 Million CAD | -12555.13% |
| 2017 Q3 | -2.16 Million CAD | -34.69% |
| 2017 Q1 | -3.36 Million CAD | -17508.11% |
| 2017 Q2 | -1.6 Million CAD | 52.23% |
| 2017 Q4 | -2.16 Million CAD | -0.14% |
| 2016 Q3 | -45.84 Thousand CAD | 24.74% |
| 2016 Q2 | -60.91 Thousand CAD | -2845.25% |
| 2016 Q1 | 2219.00 CAD | 126.58% |
| 2016 FY | -73.49 Thousand CAD | 34.29% |
| 2016 Q4 | -19.09 Thousand CAD | 58.35% |
| 2015 FY | -111.84 Thousand CAD | -144.67% |
| 2015 Q4 | -8348.00 CAD | -29.53% |
| 2015 Q3 | -6445.00 CAD | 63.81% |
| 2015 Q2 | -17.8 Thousand CAD | -45.55% |
| 2015 Q1 | -12.23 Thousand CAD | 53.36% |
| 2014 FY | -45.71 Thousand CAD | 62.82% |
| 2014 Q1 | -4498.00 CAD | 64.2% |
| 2014 Q2 | -21.11 Thousand CAD | -369.32% |
| 2014 Q3 | -55.57 Thousand CAD | -163.24% |
| 2014 Q4 | -26.23 Thousand CAD | 52.79% |
| 2013 Q2 | -13.92 Thousand CAD | -86.32% |
| 2013 Q4 | -12.56 Thousand CAD | -66.59% |
| 2013 FY | -122.96 Thousand CAD | 0.0% |
| 2013 Q3 | -7542.00 CAD | 45.85% |
| 2013 Q1 | -7476.00 CAD | 41.98% |
| 2012 Q4 | -12.88 Thousand CAD | 85.47% |
| 2012 Q3 | -88.67 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | -132.35% |
| Arrayit Corporation | -3.62 Million USD | 20.337% |
| Atlantic International Corp. | -5.73 Million USD | 49.659% |
| Biocept, Inc. | -31.98 Million USD | 90.977% |
| Bioqual, Inc. | -19.63 Thousand USD | -14594.933% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -273.738% |
| DermTech, Inc. | -103.73 Million USD | 97.218% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.116% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 86.146% |
| iMD Companies, Inc. | -175.44 Thousand USD | -1544.831% |
| IDenta Corp. | -1499.00 USD | -192414.41% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 202.917% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 7558.752% |
| InVitro International | -25.33 Thousand USD | -11288.733% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 59.481% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -4865.912% |
| Medical Imaging Corp. | -819.48 Thousand USD | -252.149% |
| NovelStem International Corp. | -3.52 Million USD | 18.152% |
| Optigenex Inc. | 1.39 Million USD | 307.486% |
| PharmChem, Inc. | 973.14 Thousand USD | 396.542% |
| Proteome Sciences plc | -1.62 Million USD | -78.025% |
| Response Genetics, Inc | -21.37 Million USD | 86.5% |
| Rennova Health, Inc. | -1.4 Million USD | -104.734% |
| RushNet, Inc. | -684.7 Thousand USD | -321.465% |
| ScreenPro Security Inc. | -2.59 Million USD | -11.316% |
| Stella Diagnostics Inc. | -11.42 Million USD | 74.746% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 62.748% |
| Todos Medical Ltd. | -9.74 Million USD | 70.396% |